23 November 2021 - The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with six monthly paliperidone palmitate were relapse free at the end of the 12 month double-blind phase

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the approval of the long-acting atypical antipsychotic therapy Byannli (6 monthly paliperidone palmitate) by the European Commission for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate or 3 monthly paliperidone palmitate.

Read Janssen press release